Drug Profile
Research programme: diabetes therapy - Roche/Vernalis
Alternative Names: diabetes therapy research programme - Roche/VernalisLatest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Roche; Vernalis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 14 Jan 2005 Discontinued - Preclinical for Diabetes mellitus (unspecified route)
- 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis